ACME Laboratories Ltd

ACME Laboratories Ltd has a debt-to-equity ratio of 0.93, indicating a moderate reliance on debt financing, and a current ratio of 1.15, suggesting limited short-term liquidity cushion. The company's free cash flow of 479,024,350 BDT is significantly lower than its operating cash flow of 3,182,659,590 BDT, reflecting high capital expenditures of 3,080,664,730 BDT in the latest period. The negative net cash position after subtracting total debt highlights a potential liquidity constraint. The company's profitability metrics show a return on equity (ROE) of 9.08% and a return on assets (ROA) of 4.16%, both below the industry median for pharmaceutical firms, which typically exceed 10% ROE and 5% ROA. Gross profit of 15,184,675,830 BDT represents 42.3% of revenue, which is in line with the industry average, but operating income of 6,775,740,000 BDT (18.9% of revenue) is below the median for the sector. ACME Laboratories Ltd's revenue is concentrated in a single business segment, with no disclosed geographic diversification in the latest financials. This lack of diversification increases exposure to regional regulatory, economic, and market risks. The company's revenue concentration in a single segment is a structural risk factor, as it lacks the buffer of multiple revenue streams. The company's revenue growth is expected to remain flat in the current fiscal year, with a marginal increase of 0.5% year-over-year, and a projected 1.2% growth in the next fiscal year. This growth trajectory is below the industry average of 3-5% annual revenue growth for pharmaceutical firms, which is driven by new product launches and market expansion. The company's capital expenditures are expected to remain high in the near term, which could constrain free cash flow and limit reinvestment capacity. The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could necessitate additional financing in the near term. The dilution risk is low, as the number of shares outstanding has not changed between basic and diluted shares, and no recent equity issuance or ATM programs are disclosed. The company's capital structure is stable, but its reliance on long-term debt (24,915,374,340 BDT) could increase interest rate sensitivity. Recent filings and transcripts indicate no material changes in the company's operations or strategy. The latest actual EPS of 10.89 BDT and revenue of 26,947,708,020 BDT align with analyst expectations, suggesting stable performance in the near term. No significant regulatory or litigation risks are disclosed in the latest filings.